Sleep Quality Mediates the Effect of Sensitization-Associated Symptoms, Anxiety, and Depression on Quality of Life in Individuals with Post-COVID-19 Pain

Juan C. Pacho-Hernández 1, César Fernández-de-las-Peñas 2,*, Stella Fuensalida-Novo 2, Carmen Jiménez-Antona 2, Ricardo Ortega-Santiago 2, and Margarita Cigarán-Mendez 1

1 Department of Psychology, Universidad Rey Juan Carlos, 28922 Alcorcón, Spain
2 Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos (URJC), 28922 Alcorcón, Spain
* Correspondence: cesarfdlp@yahoo.es or cesar.fernandez@urjc.es; Tel.: +34-914-888-884

Abstract: A better understanding of biological and emotional variables associated with health-related quality of life in people with long-COVID is needed. Our aim was to identify potential direct and indirect effects on the relationships between sensitization-associated symptoms, mood disorders such as anxiety/depressive levels, and sleep quality on health-related quality of life in people suffering from post-COVID-19 pain. One hundred and forty-six individuals who were hospitalized due to COVID-19 during the first wave of the pandemic and suffering from long-term post-COVID-19 pain completed different patient-reported outcome measures (PROMs), including clinical features, symptoms associated with sensitization of the central nervous system (Central Sensitization Inventory), mood disorders (Hospital Anxiety and Depressive Scale), sleep quality (Pittsburgh Sleep Quality Index), and health-related quality of life (paper-based five-level version of EuroQol-5D) in a face-to-face interview conducted at 18.8 (SD 1.8) months after hospitalization. Different mediation models were conducted to assess the direct and indirect effects of the associations among the different variables. The mediation models revealed that sensitization-associated symptomatology and depressive levels directly affected health-related quality of life; however, these effects were not statistically significant when sleep quality was included. In fact, the effect of sensitization-associated symptomatology on quality of life ($\beta = -0.10$, 95% CI $-0.1736$, $-0.0373$), the effect of depressive levels on quality of life ($\beta = -0.09$, 95% CI $-0.1789$, $-0.0314$), and the effect of anxiety levels on quality of life ($\beta = -0.09$, 95% CI $-0.1648$, $-0.0337$) were all indirectly mediated by sleep quality. This study revealed that sleep quality mediates the relationship between sensitization-associated symptoms and mood disorders (depressive/anxiety levels) with health-related quality of life in individuals who were hospitalized with COVID-19 at the first wave of the pandemic and reporting post-COVID-19 pain. Longitudinal studies will help to determine the clinical implications of these findings.

Keywords: post-COVID-19; sensitization; depression; anxiety; sleep; quality of life

1. Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, responsible for coronavirus disease 2019 (COVID-19), is primarily considered a virus affecting the respiratory system; however, a multisystemic affection including neurological, gastrointestinal, and cardiological manifestations, as well as multiple organ failure, have been seen in severe COVID-19 patients [1]. The affection of different systems leads to a plethora of symptoms during the acute phase of the infection such as fever, dyspnea, throat pain, diarrhea, chest pain, confusion, and others [2]. The appearance of the SARS-CoV-2 virus has represented a worldwide sanitary crisis due to the billions of infected individuals and the millions of deaths.
Additionally, COVID-19 has evolved to a second outbreak, i.e., the presence of long-lasting symptoms several weeks or months after surviving SARS-CoV-2 acute infection, a condition called long-COVID [3] or post-COVID-19 [4]. Evidence supports the idea that almost 60% of COVID-19 survivors experience different post-COVID symptoms, at least during the first year after the acute infection [5–7]. More than 50 post-COVID-19 symptoms have been described, with fatigue, dyspnea, pain, or cognitive problems being the most prevalent [8].

Patients with post-COVID-19 report lower health-related quality of life (HRQoL) [9] and a reduction of daily living activities [10]. Soriano et al., in a Delphi consensus study, have recently included functional repercussions into the definition of the post-COVID-19 condition: “. . . these symptoms generally have an impact on everyday function . . . ” [4]. In fact, increasing evidence shows the potential burden for healthcare systems that post-COVID-19 represents [11]. Accordingly, identification of factors associated with HRQoL in people with the post-COVID-19 condition is essential.

Pain is an underestimated post-COVID-19 symptom that can generate a potential burden to the society [12]. The prevalence rate of post-COVID-19 pain symptomatology ranges between 15% and 50%, depending on the study [13,14]. Post-COVID-19 pain symptoms can exhibit musculoskeletal [15] or neuropathic [16] features in 45% and 25% of the subjects, respectively. Musculoskeletal post-COVID-19 pain is perceived in any part of the body, but the upper and lower extremities are the most prevalent locations [14,15]. Others have reported incidence rates ranging from 1.7% to 33.9% for headache, from 1.5% to 61% for myalgia or arthralgia, from 1.6% to 17.7% for chest pain, and from 1.9% to 14.5% for abdominal pain [17]. The most accepted theory explaining post-COVID-19 pain is that the systemic inflammatory–immune response (i.e., long-lasting cytokine storm) can lead to an excitability of peripheral/central nervous systems throughout direct/indirect pain pathways [18,19]. A prolonged excitability of the nervous system could promote the presence of sensitization mechanisms in these patients. In fact, it has been hypothesized that post-COVID-19 pain could be classified as a “nociplastic condition”. Nociplastic pain is defined as “pain that arises from altered nociception without clear evidence of actual or threatened tissue damage causing the activation of peripheral nociceptors or evidence for disease or lesion of the somatosensory system causing pain” [20]. The first rational for considering post-COVID-19 pain as a nociplastic condition is the increasing evidence suggesting the presence of sensitization, the basis of nociplastic pain, in individuals with post-COVID-19 pain [21,22]. Another rational for considering post-COVID-19 pain as a nociplastic condition is the presence of central-nervous-system-derived symptoms, e.g., fatigue, sleep problems, depression, anxiety, and memory loss, which are common in nociplastic pain [23] and also in individuals with the post-COVID-19 condition [5–7]. Finally, some studies have also revealed that almost 60% of individuals with post-COVID-19 pain exhibit multiple pain sites [24] and that also 30% of patients share clinical features with fibromyalgia syndrome [25].

In addition to physical symptoms, people with the post-COVID-19 condition also present emotional symptomatology. Anxiety and depressive symptoms are prevalent at the acute phase of SARS-CoV-2 infection [26,27] but also at the post-COVID-19 phase [28]. The presence of physical and emotional symptoms in patients with the post-COVID-19 condition supports the observation that biological and behavioral factors interact in a COVID-19 context [29]. It has been recently found that higher depressive symptomatology is associated with a higher risk of physical post-COVID-19 symptoms such as pain and dyspnea [30]. In fact, the interaction between anxiety and depressive levels with pain is supported in the literature since mood disorders can contribute to chronic pain via supra-spinal mechanisms and emotional modulation of pain [31]. Therefore, a better understanding of the interactions between sensitization-associated symptoms, mood disorders, sleep, and HRQoL in people with post-COVID-19 pain may assist clinicians to determine better therapeutic programs for this population.
Accordingly, the purpose of this study was to identify the direct and indirect effects on the relationships between sensitization-associated symptoms and emotional disorders on HRQoL in a sample of previously hospitalized COVID-19 survivors with long-term post-COVID-19 pain.

2. Methods

2.1. Participants

From all individuals hospitalized during the first wave of the COVID-19 pandemic (March–April 2020) due to an acute SARS-CoV-2 infection from three urban hospitals in Madrid (Spain), a randomly sample of 200 individuals were included into an anonymous electronic database and invited to participate in a face-to-face interview. To be selected, patients should fulfill the following criteria: (1) diagnosis of SARS-CoV-2 infection by real-time reverse transcription-polymerase chain reaction (RT-PCR) assay of nasopharyngeal/oral swab sample and clinical and radiological findings at hospital admission; (2) hospitalization during the first wave of the pandemic; (3) presence of post-COVID-19 pain symptoms starting no later than two months after hospitalization and lasting for at least three months [4]; and (4) absence of underlying medical conditions that could best explain pain, e.g., arthritis. Exclusion criteria consisted of (1) pre-existing history of chronic pain symptoms before SARS-CoV-2 infection and (2) pre-existing medical comorbidity explaining pain symptoms.

This study was approved by all the Ethics Committees of all the involved institutions (INDIVAL Cantabria 2020.416, HUFA 20/126, URJC0907202015920, HSO25112020, HUIL/092-20). All participants provided their written informed consent prior to their inclusion.

Participants were scheduled for a face-to-face interview with an experienced assessor where they fulfilled demographic data (i.e., age, sex, height, and weight), clinical data (i.e., intensity and duration of pain), and the following PROMS: sensitization-associated symptoms, anxiety and depressive symptoms (considered as the independent variables), sleep quality (considered as the mediating variable), and health-related quality of life (considered as the dependent variable). Data from hospitalization were obtained from medical records.

2.2. Dependent Variable: Health-Related Quality of Life

Health-related quality of life (HRQoL) was assessed with the paper-based five-level version of EuroQol-5D (EQ-5D-5L) [32]. This PROM assesses the following items: mobility, self-care, daily life activities, pain symptoms, and depression/anxiety into 5-point Likert scales ranging from 0 (no problem) to 4 (severe problems) points. Responses are converted into a single index number ranging from 0 (health state judged to be equivalent to death) to 1 (optimal health) by applying crosswalk index values for Spain life [33]. The EQ-5D-5L has shown excellent test–retest reliability in individuals with post-COVID-19 (ICC 0.86) [32].

2.3. Mediating Variable: Sleep Quality

The Pittsburgh Sleep Quality Index (PSQI) was the PROM used to assess sleep quality [34]. This PROM includes 19 questions assessing different aspects of sleep, e.g., usual bedtime, wake-up time, number of hours slept, and time needed to fall asleep in a 4-point Likert scale ranging from 0 to 3 points. The total score ranges from 0 to 21 points, where ≥8.0 points are indicative of being poor sleeper [34]. The PSQI has exhibited excellent test–retest reliability patients with primary insomnia (ICC 0.87) [35].

2.4. Independent Variables: Sensitization-Associated Symptoms and Mood Disorders

The Central Sensitization Inventory (CSI) was used to evaluate the presence of sensitization-associated symptomatology [36]. This PROM evaluates the presence of 25 symptoms associated with sensitization on a 5-point Likert scale. The total score ranges from 0 to 100 points. A score > 40 points suggests the presence of symptoms related to sensi-
Anxiety and depressive symptoms were assessed with the Hospital Anxiety and Depression Scale (HADS) [40]. Each scale includes 7 items evaluating anxiety (HADS-A) or depressive (HADS-D) symptoms on a 4-point Likert scale (0–3). The score of each subscale ranges from 0 to 21 points, where ≥12 points on the HADS-A are indicative of anxiety symptoms and ≥10 points on the HADS-D indicate of depressive symptoms [41]. A recent study has revealed that both scales of the HADS exhibit good internal consistency in people with the post-COVID-19 condition [40].

2.5. Statistical Analysis

Descriptive (means, standard deviations) and frequency analyses were calculated using the statistical program IBM SPSS 27.0. In addition, the PROCESS macro version 4.1 [42] for SPSS was used for testing the simple mediation models depicted in Figure 1, as well as for calculating total and direct effects of each independent variable (sensitization-associated symptoms, depressive levels, anxiety levels) on the dependent variable (HRQoL), and also the indirect effect of sleep quality (the proposed mediating variable) in the relationship between each independent variable with the dependent variable.

![Mediation models with standardized coefficients. Model 1. $a_1 = \text{beta value of sensitization-associated symptoms on sleep quality}$; $b_1 = \text{beta value of sleep quality on quality of life}$; $c_1 = \text{total effect of sensitization-associated symptoms on quality of life}$; $c_1' = \text{direct effect of sensitization-associated symptoms on quality of life once sleep quality is included in the model}$. Model 2. $a_2 = \text{beta value of depressive levels on sleep quality}$; $b_2 = \text{beta value of sleep quality on quality of life}$; $c_2 = \text{total effect of depressive levels on quality of life}$; $c_2' = \text{direct effect of depressive levels on quality of life once sleep quality has been included in the model}$. Model 3. $a_3 = \text{beta value of anxiety on sleep quality}$; $b_3 = \text{beta value of sleep quality on quality of life}$; $c_3 = \text{total effect of anxiety on quality of life}$; $c_3' = \text{direct effect of anxiety on quality of life once sleep quality has been included in the model}$. * $p < 0.05$; ** $p < 0.01$.](image)

PROCESS uses a bootstrapping method that allows for the calculation of the total effect, the direct effect, and the indirect effect with 5,000 resamples and bias-corrected 95% confidence intervals. This method does not assume normality of sampling distribution and has been proven to have the highest power and the best type I error control [43]. Statistical
significance of the mediation effect was determined if the confidence interval of the indirect effect excluded zero, indicating that the indirect effect was significant and was different from zero [42]. All results were considered significant at the level \( p < 0.05 \).

3. Results

3.1. Descriptive Analysis

From 200 randomly selected individuals with the post-COVID-19 condition screened for participation, after verifying that they fulfilled all criteria, 146 (53.4% women, age: 57.5 ± 12 years) patients were finally included and analyzed. The reason for exclusion of the 54 participants was because they did not report post-COVID pain. Participants were assessed at a mean of 18.8 ± 1.8 months after hospitalization. Table 1 shows the descriptive data of the sample.

| Table 1. Means and standard deviations of study variables. |
|----------------------------------------------------------|
|                                | Mean   | SD      |
|--------------------------------|--------|---------|
| Central sensitization (CSI, 0–100) | 33.9   | 17.25   |
| Depression (HADS-D, 0–21)        | 5.0    | 4.3     |
| Sleep quality (PSQI, 0–21)       | 8.1    | 4.3     |
| Anxiety (HADS-A, 0–21)           | 5.3    | 4.2     |
| Quality of life (EQ-5D-5L, 0–1)   | 0.8    | 0.2     |

CSI: Central Sensitization Inventory; EQ-5D-5L: EuroQol-5D questionnaire; HADS: Hospital Anxiety and Depression Scale; PSQI: Pittsburg Sleeping Quality Index; SD: standard deviation.

3.2. Mediation Analysis

The regression coefficients of the mediation models can be observed in Table 2. The first model of mediation revealed that higher CSI score was significantly associated with higher PSQI scores (\( \beta = 0.39, p < 0.01 \)), and higher PSQI scores were also significantly associated with lower scores in HRQoL (\( \beta = −0.26, p < 0.05 \)).

| Table 2. Regression coefficients of mediation analyses. |
|--------------------------------------------------------|
| Coefficients                                           |
| Independent Variable | Dependent Variable | \( \beta \) | SE | t | p      | \( R^2 \) | Lower Limit | Upper Limit |
| CSI              | PSQI               | 0.39       | 0.01 | 5.08 | 0.001 ** | 0.39 | 0.0592 | 0.1344 |
| Total effect CSI | CSI                | −0.19      | 0.00 | −2.44 | 0.01 *   | 0.19 | −0.0042 | −0.0004 |
| Direct effect CSI | PSQI               | −0.26      | 0.00 | −3.05 | 0.001 ** | 0.31 | −0.0205 | −0.0044 |
| Indirect effect CSI | Eq-5D-5L           | −0.10      | 0.03 |        |         |     | −0.1736 | −0.0373 |
| Model 2         | HADS-D             | 0.35       | 0.07 | 4.53  | 0.001 ** | 0.35 | 0.1988 | 0.5058 |
| Total effect HADS-D | Eq-5D-5L         | −0.17      | 0.00 | −2.12 | 0.03 *   | 0.17 | −0.0158 | −0.0006 |
| Direct effect HADS-D | PSQI              | −0.27      | 0.00 | −3.21 | 0.001 ** | 0.30 | −0.0209 | −0.0050 |
| Indirect effect HADS-D | Eq-5D-5L         | −0.09      | 0.03 |        |         |     | −0.1789 | −0.0314 |
| Model 3         | HADS-A             | 0.32       | 0.08 | 4.00  | 0.001 ** | 0.31 | 0.1625 | 0.4795 |
| Total effect HADS-A | Eq-5D-5L         | −0.14      | 0.00 | −1.73 | 0.08     | 0.14 | −0.0147 | 0.0010 |
| Direct effect HADS-A | PSQI              | −0.05      | 0.00 | −0.62 | 0.53     | 0.30 | −0.0105 | 0.0054 |
| Indirect effect HADS-A | Eq-5D-5L         | −0.28      | 0.00 | −3.38 | 0.001 ** | 0.30 | −0.0213 | −0.0056 |
|                        |                   | −0.09      | 0.03 |        |         |     | −0.1648 | −0.0337 |

SE: standard error; * \( p < 0.05 \); ** \( p < 0.01 \); CSI: Central Sensitization Inventory; Eq-5D-5L: EuroQol-5D questionnaire; HADS: Hospital Anxiety and Depression Scale; PSQI: Pittsburg Sleeping Quality Index.
The total effect of sensitization-associated symptoms (CSI) on quality of life was significant ($\beta = -0.19$, $p < 0.05$), showing a negative relationship. However, the direct effect of sensitization-associated symptoms on quality of life was not significant after including sleep quality in the model. In fact, the indirect effect of sensitization-associated symptoms on quality of life through sleep quality was statistically significant ($\beta = -0.10$, 95% CI $-0.1736$, $-0.0373$, Figure 1).

The second model of mediation showed that higher HADS-D scores were significantly associated with higher PSQI scores ($\beta = 0.35$, $p < 0.01$), and that higher PSQI scores were significantly associated with lower scores in HRQoL ($\beta = -0.27$, $p < 0.01$). The total effect of depression on quality of life was significant ($\beta = -0.17$, $p < 0.05$), indicating that higher depressive levels were associated with worse quality of life. Again, the direct effect of depression on quality of life was not significant after introducing sleep quality in the model, since the indirect effect of depression on quality of life through sleep quality was statistically significant ($\beta = -0.09$, 95% CI $-0.1789$, $-0.0314$, Figure 1).

Finally, data obtained in the third mediation model pointed out that higher HADS-A scores significantly predicted higher PSQI scores ($\beta = 0.31$, $p < 0.01$), and higher scores in PSQI were again significantly associated with lower scores in HRQoL ($\beta = -0.28$, $p < 0.01$). In turn, neither the total nor the direct effect of anxiety on quality of life was statistically significant. Finally, an indirect effect of anxiety on quality of life through sleep quality was statistically significant ($\beta = -0.09$, 95% CI $-0.1648$, $-0.0337$, Figure 1).

4. Discussion

The current study demonstrated that sleep quality mediates the relationship between symptoms associated with sensitization and mood disorders, i.e., anxiety/depressive symptoms, with HRQoL in individuals who have been hospitalized due to SARS-CoV-2 acute infection and suffering from long-term post-COVID-19 pain.

Previous studies suggested the presence of sensitization-associated symptoms in patients with the post-COVID-19 condition [21,22]. These studies used the CSI for evaluating these associated symptoms; however, the exclusive use of the CSI score for identifying sensitization in people with chronic pain is not recommended because this PROM overlaps with the psychological variables, such as emotional stress [44], and because only one PROM is not able to capture the complexity of central sensitization, a process involving excitability of the central nervous system [45]. We found that sensitization-associated symptoms (e.g., CSI) and depressive symptoms (i.e., HADS-D), but not anxiety symptoms (e.g., HADS-A), had direct effects on HRQoL in people with post-COVID-19 pain. Interestingly, all the effects on HRQoL from these variables were mediated by sleep quality.

These results would agree with the assumption that the CSI score can exhibit an overlap with the emotional stress construct, particularly depression, since both sensitization-associated symptoms and depressive levels exhibited similar direct effects on HRQoL, but their effect was mediated by the quality of sleep. The association between depression, sleep quality, and sensitization-associated symptoms is based on the fact that depression and sleep disturbances are able to trigger hyperalgesic responses in the nervous system via supraspinal pain mechanism and emotional modulation of pain [31,46]. Another hypothesis could be the affection of the renin–angiotensin system, hence affecting the central nervous system, by the virus itself [47].

The relevance of depression as a factor associated with chronic pain is supported in the literature [48]. Additionally, the relevance of depressive symptoms in people with the post-COVID-19 condition is also clear in the literature [49]. The presence of depressive symptoms has been associated to higher risk of other post-COVID-19 symptoms such as fatigue [50] or dyspnea [30]. This interaction between physical and emotional post-COVID-19 symptoms would explain a worse HRQoL experienced by the patients. Potential psychopathological mechanisms underlying depressive symptoms in subjects with the post-COVID-19 condition are mainly related to the inflammation triggered by an exaggerated immune response to the viral acute infection (i.e., cytokine storm) and to the
persistent psychological burden during (e.g., severity of the disease, or hospitalization) and after (e.g., isolation, post-traumatic stress, or uncertainty about prognosis) the acute infection [49]. Since anxiety and depressive symptoms can be present up to several years after the infection [51], continuous monitoring of this symptom will be important for determining the evolution of HRQoL in these patients. Nevertheless, the effects of depressive levels on HRQoL were mainly mediated by the quality of sleep.

The most important finding of this study is the role of sleep quality in individuals with post-COVID-19 pain. That sleep problems are prevalent in people with the post-COVID-19 condition is supported by available data [52]. Patients with the post-COVID-19 condition report greater difficulty falling asleep at their desired bedtime and also waking up at their desired wake time [53]. El Sayed et al. observed that sleep disturbances in post-COVID-19 patients were associated with physical and mental aspects of quality of life [54]. However, this study only analyzed the linear association between sleep quality and HRQoL. Our results further support a role of sleep in patients with post-COVID-19 pain. Although poor sleep quality has been associated with increased depressive and anxiety levels in post-COVID-19 patients [55], our study has shown that sleep quality indirectly mediated the relationship between these emotional disorders and HRQoL in those with pain symptomatology. The direction of this relationship can be bidirectional since depressive or anxiety symptoms may induce worse sleep quality, but poor sleep quality can perpetuate or potentiate these emotional disorders. The mediation effect of worse sleep quality in HRQoL may be related to associated repercussions, such as tiredness or lack of energy [56]. Independently of the direction of this association, current data suggest that poor sleep quality, depressive levels, anxiety levels, and sensitization-associated symptoms display complex relationships, and all likely influence each other in a vicious cycle in people with the post-COVID-19 condition.

The results from the current study have potential clinical implications for treatment of patients with post-COVID-19 pain. First, management of sensitization-associated symptomatology and depression may induce an improvement in HRQoL (due to their direct effects). In fact, evidence supports the use of resistance (e.g., 1–2 sets of 8–10 repetitions at 30–80% of 1RM) and aerobic (e.g., 5 to 30 min at moderate intensity) exercise programs for the management of HRQoL and emotional stress in patients with the post-COVID-19 condition [57]. A rationale for this improvement would be that exercise effects are mainly mediated by the central nervous system, and, accordingly, an effect in the nervous system of a patient with the post-COVID-19 condition would be expected [58]. Second, direct treatment of sleep could improve HRQoL in these patients (due to their indirect effect of HRQoL). Nevertheless, a meta-analysis identified that cognitive behavioral therapy was effective for managing sleep in people with chronic pain, but its direct effect on HRQoL and psychological health was not clear [59]. Accordingly, treatment of HRQoL in individuals with post-COVID-19 pain symptoms should be multimodal by targeting all variables identified in the current study, i.e., sensitization-associated symptoms, depressive levels, anxiety levels, and sleep quality. Obviously, those therapeutic strategies targeting one of these factors will have an indirect effect in those interconnected variables. Future studies evaluating the treatment strategies for patients with post-COVID-19 pain should include the topics identified in the current study.

The current study has some limitations. First, current data can only be applicable to previously hospitalized COVID-19 survivors. We do not currently know if the same associations will be seen in non-hospitalized COVID-19 survivors. However, we did not collect data regarding COVID-19 severity and other factors associated with hospitalization. Second, we used a cross-sectional design, and the mediation analyses were correlational, precluding any causal inference. Third, we did not assess the presence of depressive and anxiety symptoms at the acute phase of the infection or before the infection; accordingly, we cannot exclude the potential presence of these emotional disorders before the acute infection. Further, the levels of depression and anxiety observed in our sample of long haulers could be considered small. Fourth, the use of the CSI for assessing the presence of
sensitization-associated symptoms may be confounded by coping/emotional traits. Finally, we did not analyze the presence of post-traumatic stress symptoms, which is common in people exposed to the trauma resulting from an infectious disease outbreak such as COVID-19 [60]. We do not currently know the role of post-traumatic stress in HRQoL in individuals with long-COVID. Future studies assessing the role of post-traumatic stress in post-COVID-19 are needed.

5. Conclusions

The current study identified that sleep quality mediates the relationship between sensitization-associated symptoms, anxiety, and depressive levels with health-related quality of life in previously hospitalized COVID-19 survivors with post-COVID-19 pain. Management of cognitive and emotional symptoms in individuals with post-COVID-19 pain could exhibit a direct and indirect effect on health-related quality of life.

Author Contributions: Conceptualization, all authors; methodology, all authors; software, J.C.P.-H.; validation, all authors; investigation, all authors; resources, all authors; writing—original draft preparation, all authors; writing—review and editing, all authors; visualization, all authors; supervision, C.F.-d.-I.-P. and M.C.-M.; project administration, S.F.-N., C.J.-A. and R.O.-S. All authors have read and agreed to the published version of the manuscript.

Funding: The LONG-COVID-EXP-CM is supported by a grant of Comunidad de Madrid y la Unión Europea, a través del Fondo Europeo de Desarrollo Regional (FEDER), Recursos REACT-UE del Programa Operativo de Madrid 2014-2020, financiado como parte de la respuesta de la Unión a la pandemia de COVID-19. The sponsor had no role in the design, collection, management, analysis, or interpretation of the data, nor the draft, review, or approval of the manuscript or its content. The authors were responsible for the decision to submit the manuscript for publication, and the sponsor did not participate in this decision.

Institutional Review Board Statement: This study was approved by all the Local Institutional Ethics Committees (INDIVAL Cantabria 2020.416, HUFA 20/126, URJC0907202015920, HSO25112020, HUIL/092-20).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Rabaan, A.A.; Al-Ahmed, S.H.; Al Mutair, A.; Alhumaid, S.; Sule, A.A.; Tirupathi, R.; Fawzy, M.; Muhammad, J.; Khan, A.; Hasan, A.; et al. Immunopathogenesis and immunobiology of SARS-CoV-2. *Infec. Med.* 2021, 29, 167–180. [CrossRef]

2. Zheng, K.I.; Feng, G.; Liu, W.Y.; Targher, G.; Byrne, C.D.; Zheng, M.H. Extrapulmonary complications of COVID-19: A multisystem disease? *J. Med. Virol.* 2021, 93, 323–335. [CrossRef]

3. Fernández-de-las-Peñas, C. Long COVID: Current definition. *Infection* 2022, 50, 285–286. [CrossRef]

4. Soriano, J.B.; Murthy, S.; Marshall, J.C.; Relan, P.; Diaz, J.V.; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect. Dis.* 2022, 22, e102–e107. [CrossRef]

5. Fernández-de-las-Peñas, C.; Palacios-Ceña, D.; Gómez-Mayordomo, V.; Florencio, L.L.; Cuadrado, M.L.; Plaza-Manzano, G.; Navarro-Santana, M. Prevalence of Post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis. *Eur. J. Int. Med.* 2021, 30, 3367–3381. [CrossRef]

6. Taha, R.M.; Kashour, Z.; Kashour, T.; Berbari, E.F.; Alkattan, K.; Tleyjeh, I.M. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: A systematic review and meta-analysis. *Clin. Microbiol. Infect.* 2022, 28, 657–666. [CrossRef]

7. Han, Q.; Zheng, B.; Daines, L.; Sheik, A. Long-term sequelae of COVID-19: A systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. *Pathogens* 2022, 11, 269. [CrossRef]

8. Lopez-Leon, S.; Wegman-Ostrosky, T.; Perelman, C.; Sepulveda, R.; Rebollo, P.A.; Cuapio, A.; Villapol, S. More than 50 Long-term effects of COVID-19: A systematic review and meta-analysis. *Sci. Rep.* 2021, 11, 16144. [CrossRef]

9. Amdal, C.D.; Pe, M.; Falk, R.S.; Piccinin, C.; Bottomley, A.; Arraras, J.I.; Darlington, A.S.; Høfø, K.; Holzner, B.; Jergensen, N.M.H.; et al. Health-related quality of life issues, including symptoms, in patients with active COVID-19 or post COVID-19: A systematic literature review. *Qual. Life Res.* 2021, 30, 3367–3381. [CrossRef]
Brain Sci. 2022, 12, 1363

10. Pizarro-Pennaroli, C.; Sánchez-Rojas, C.; Torres-Castro, R.; Vera-Uribe, R.; Sanchez-Ramirez, D.C.; Vasconcello-Castillo, L.; Solís-Navarro, L.; Rivera-Lillo, G. Assessment of activities of daily living in patients post COVID-19: A systematic review. PeerJ 2021, 9, e10126. [CrossRef]

11. Menges, D.; Ballouz, T.; Anagnostopoulos, A.; Aschmann, H.E.; Domenghino, A.; Fehr, J.S.; Puhan, M.A. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. PLoS ONE 2021, 16, e0254323. [CrossRef]

12. Bileviciute-Ljungar, I.; Norrefalk, J.R.; Borg, K. Pain burden in post-COVID-19 syndrome following mild COVID-19 infection. J. Clin. Med. 2022, 11, 771. [CrossRef]

13. Fernández-de-las-Peñas, C.; Navarro-Santana, M.; Plaza-Manzano, G.; Palacios-Ceña, D.; Arendt-Nielsen, L. Time course prevalence of post-COVID pain symptoms of musculoskeletal origin in patients who had survived severe acute respiratory syndrome coronavirus 2 infection: A systematic review and meta-analysis. Pain 2022, 163, 1220–1231. [CrossRef]

14. Soares, F.H.C.; Kubota, G.T.; Fernandes, A.M.; Hojo, B.; Couras, C.; Costa, B.V.; Lapa, J.D.d.; Braga, L.M.; de Almeida, M.M.; da Cunha, I.P.M.; et al. Prevalence and characteristics of new-onset pain in COVID-19 survivors, a controlled study. Eur. J. Pain 2021, 25, 1342–1354. [CrossRef]

15. Fernández-de-las-Peñas, C.; de-la-LLave-Rincón, A.I.; Ortega-Santiago, R.; Ambite-Quesada, S.; Gómez-Mayordomo, V.; Cuadrado, M.I.; Arias-Navalón, J.A.; Hernández-Barrera, V.; Martín-Guerrero, J.D.; Pellicer-Valero, O.J. Prevalence and risk factors of musculoskeletal pain symptoms as long-term post-COVID sequelae in hospitalized COVID-19 survivors: A multicenter study. Pain 2022, 163, e689–e996. [CrossRef]

16. Herrero-Montes, M.; Fernández-de-las-Peñas, C.; Ferrer-Pargada, D.; Tello-Mena, S.; Cancela-Cilleruelo, I.; Rodríguez-Jiménez, J.; Palacios-Ceña, D.; Parás-Bravo, P. Prevalence of neuropathic component in post-COVID pain symptoms in previously hospitalized COVID-19 survivors. Int. J. Clin. Pract. 2022, 2022, 3532917. [CrossRef]

17. Weng, L.M.; Su, X.; Wang, X.Q. Pain symptoms in patients with Coronavirus Disease (COVID-19): A literature review. J. Pain Res. 2021, 14, 147–159. [CrossRef]

18. Cascella, M.; Del Gaudio, A.; Vittori, A.; Bimonte, S.; Del Prete, P.; Forte, C.A.; Cuomo, A.; De Blasio, E. COVID-Pain: Acute and persisting pain in COVID-19 survivors exhibiting post-COVID pain. Pain Pract. 2022, in press. [CrossRef] [PubMed]

19. Shahanna, H.; Nelson, A.M.; Kissoon, N.; Narouze, S. The COVID-19 pandemic and its consequences for chronic pain: A narrative review. Anaesthesia 2022, 77, 1039–1050. [CrossRef]

20. Kosek, E.; Clauw, D.; Nijs, J.; Baron, R.; Gilron, I.; Harris, R.E.; Mico, J.-A.; Rice, A.S.C.; Sterling, M. Chronic nociceplastic pain affecting the musculoskeletal system: Clinical criteria and grading system. Pain 2021, 162, 2629–2634. [CrossRef]

21. Fernández-de-las-Peñas, C.; Parás-Bravo, P.; Ferrer-Pargada, D.; Cancela-Cilleruelo, I.; Rodríguez-Jiménez, J.; Nijs, J.; Arendt-Nielsen, L.; Herrero-Montes, M. Sensitization symptoms are associated with psychological and cognitive variables in COVID-19 survivors exhibiting post-COVID pain. Pain Pract. 2022, in press. [CrossRef] [PubMed]

22. Goudman, L.; De Smedt, A.; Norren, M.; Moens, M. Is Central Sensitisation the Missing Link of Persisting Symptoms after COVID-19 Infection? J. Clin. Med. 2021, 10, 5594. [CrossRef]

23. Fitzcharles, M.A.; Cohen, S.P.; Clauw, D.J.; Littlejohn, G.; Usui, C.; Häuser, W. Nociceplastic pain: Towards an understanding of prevalent pain conditions. Lancet 2021, 397, 2098–2110. [CrossRef]

24. Oguz-Akarsu, E.; Gullu, G.; Kiliç, E.; Ding, Y.; Urasvavas, A.; Yilmaz, E.; Zarifoglu, M.; Karli, N.; Pandemic Study Team. Insight into pain syndromes in acute phase of mild-to-moderate COVID-19, Frequency, clinical characteristics, and associated factors. Eur. J. Pain 2022, 26, 492–504. [CrossRef]

25. Ursini, F.; Ciaffi, J.; Mancarella, L.; Lisi, L.; Brusi, V.; Cavallari, C.; D’Onghia, M.; Mari, A.; Borlandelli, E.; Cordella, J.F.; et al. Fibromyalgia: A new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey. RMD Open 2021, 7, e001735. [CrossRef]

26. Li, T.; Sun, S.; Liu, B.; Wang, J.; Zhang, Y.; Gong, C.; Duan, J. Prevalence and risk factors for anxiety and depression in patients with COVID-19 in Wuhan, China. Psychosom. Med. 2021, 83, 368–372. [CrossRef]

27. Liu, C.; Pan, W.; Li, L.; Li, B.; Ren, Y.; Ma, X. Prevalence of depression, anxiety, and insomnia symptoms among patients with COVID-19: A meta-analysis of quality effects model. J. Psychosom. Res. 2021, 147, 110516. [CrossRef]

28. Shanbehzadeh, S.; Tavahomi, M.; Zanjari, N.; Ebrahimi-Takamjani, I.; Amiri-Arimi, S. Physical and mental health complications post-COVID-19: A systematic review of scoping. J. Psychosom. Res. 2021, 147, 110525. [CrossRef]

29. Hall, P.A.; Sheeran, P.; Fong, G.T.; Cheah, C.S.L.; Oremus, M.; Liu-Ambrose, T.; Sakib, M.N.; Ayaz, H.; Jandu, N.; et al. Biobehavioral aspects of the COVID-19 pandemic: A review. Psychosom. Med. 2021, 83, 309–321. [CrossRef] [PubMed]

30. Bottemanne, H.; Gouraud, C.; Hulot, J.S.; Blanchard, A.; Ranque, B.; Lahrlou-Laforet, K.; Limosin, F.; Günther, S.; Lebeaux, D.; Lemogne, C. Do anxiety and depression predict persistent physical symptoms after a severe COVID-19 episode? A prospective study. Front. Psychiatry 2021, 12, 757685. [CrossRef] [PubMed]

31. Terry, E.L.; DelVentura, J.; Bartley, E.J.; Vincent, A.L.; Rhudy, J.L. Emotional modulation of pain and spinal nociception in persons with major depressive disorder (MDD). Pain 2013, 154, 2759–2768. [CrossRef] [PubMed]

32. Fernández-de-las-Peñas, C.; Rodríguez-Jiménez, J.; Monó-López-Menéndez, P.; Cancela-Cilleruelo, I.; Pardo-Hernández, A.; Hernández-Barrera, V.; Gil-de-Miguel, A. Psychometric properties of the Spanish version of the EuroQol-5D-5L in previously hospitalized COVID-19 survivors with long COVID. Sci. Rep. 2022, 12, 12605. [CrossRef] [PubMed]
33. Van Hout, B.; Janssen, M.F.; Feng, Y.J.; Kohlmann, T.; Busschbach, J.; Golicki, D.; Lloyd, A.; Scalone, L.; Kind, P.; Pickard, A.S. Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012, 15, 708–715. [CrossRef] [PubMed]
34. Buysse, D.J.; Reynolds, C.F.; Monk, T.H.; Berman, S.R.; Kupfer, D.J. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res. 1989, 28, 193–213. [CrossRef]
35. Backhaus, J.; Junghanns, K.; Broocks, A.; Riemann, D.; Hohagen, F. Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. J. Psychosom. Res. 2002, 53, 737–740. [CrossRef]
36. Mayer, T.G.; Neblett, R.; Cohen, H.; Howard, K.J.; Choi, Y.H.; Williams, M.J.; Perez, Y.; Gatchel, R.J. The development and psychometric validation of the central sensitization inventory. Pain Pract. 2012, 12, 276–285. [CrossRef]
37. Neblett, R.; Cohen, H.; Choi, Y.; Hartzell, M.M.; Williams, M.; Mayer, T.G.; Gatchel, R.J. The Central Sensitization Inventory (CSI): Establishing clinically significant values for identifying central sensitivity syndromes in an outpatient chronic pain sample. J. Pain 2013, 14, 438–445. [CrossRef]
38. Scerbo, T.; Colasurdo, J.; Dunn, S.; Unger, J.; Nijs, J.; Cook, C. Measurement properties of the central sensitization inventory: A systematic review. Pain Pract. 2018, 18, 544–554. [CrossRef]
39. Cuesta-Vargas, A.I.; Neblett, R.; Chiarotto, A.; Kregel, J.; Nijs, J.; van Wilgen, C.P.; Pitance, L.; Knezevic, A.; Gatchel, RJ.; Mayer, T.G.; et al. Dimensionality and reliability of the Central Sensitization Inventory in a pooled multi-country sample. J. Pain 2018, 19, 317–329. [CrossRef] [PubMed]
40. Fernández-de-las-Peñas, C.; Rodríguez-Jiménez, J.; Palacios-Ceña, M.; de-la-Llave-Rincón, A.I.; Fuensalida-Novo, S.; Florencio, L.L.; Ambite-Quesada, S.; Ortega-Santiago, R.; Arias-Buria, J.L.; Liew, B.X.W.; et al. Psychometric properties of the Hospital Anxiety and Depression Scale (HADS) in previously hospitalized COVID-19 patients. Int. J. Environ. Res. Public Health 2022, 19, 9273. [CrossRef]
41. Grupo de Trabajo de la Guía de Práctica Clínica para el Manejo de Pacientes con Trastornos de Ansiedad en Atención Primaria. 2008. Guías de Práctica Clínica en el SNS—UIETS N° 2006/10; Plan Nacional para el SNS del MSC, Unidad de Evaluación de Tecnologías Sanitarias, Agencia Lain Entralgo, Comunidad de Madrid: Madrid, Spain, 2008.
42. Hayes, A.F. Introduction to Mediation, Moderation, and Conditional Process Analysis: A Regression-Based Approach, 3rd ed.; The Guilford Press: New York, NY, USA, 2022.
43. Preacher, K.J.; Hayes, A.F. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav. Res. Methods 2008, 40, 879–891. [CrossRef] [PubMed]
44. Adams, G.R.; Gandhi, W.; Harrison, R.; van Reekum, C.M.; Gilron, I.; Salomons, T.V. Do “central sensitization” questionnaires reflect measures of noceboive sensitization or psychological constructs? Protocol for a systematic review. Pain Rep. 2021, 6, e962. [CrossRef] [PubMed]
45. Nijs, J.; Huysmans, E. Clinimetrics: The Central Sensitization Inventory: A useful screening tool for clinicians, but not the gold standard. J. Physiother. 2022, 68, 207. [CrossRef]
46. De Tommaso, M.; Delussi, M.; Vecchio, E.; Scruciucchio, V.; Invitto, S.; Livrea, P. Sleep features and central sensitization symptoms in primary headache patients. J. Headache Pain 2014, 15, 64. [CrossRef] [PubMed]
47. Khazaal, S.; Harb, J.; Rima, K.; Ait-Chaab, A.; Ait-Chaab, M.; Legros, C.; Wu, Y.; Cao, Z.; Abi-Khadra, Z.; El-Nahhal, A.; Lallouz, O.; Fajloun, Z.; et al. The psycho-pathophysiologic of long COVID in the Renin-Angiotensin System. Molecules 2022, 27, 2903. [CrossRef] [PubMed]
48. George, S.Z.; Coronado, R.A.; Beneckiuk, J.M.; Valencia, C.; Werneke, M.W.; Hart, D.L. Depressive symptoms, anatomical region, and clinical outcomes for patients seeking outpatient physical therapy for musculoskeletal pain. Phys. Ther. 2011, 91, 358–372. [CrossRef] [PubMed]
49. Mazza, M.G.; Palladini, M.; Poletti, S.; Benedetti, F. Post-COVID-19 depressive symptoms: Epidemiology, Pathophysiology, and pharmacological treatment. CNS Drugs 2022, 36, 681–702. [CrossRef] [PubMed]
50. Al-Jassas, H.K.; Al-Hakeim, H.K.; Maes, M. Intersections between pneumonia, lowered oxygen saturation percentage and immune activation mediate depression, anxiety, and chronic fatigue syndrome-like symptoms due to COVID-19: A nomothetic network approach. J. Affect. Disord. 2022, 15, 235–245. [CrossRef]
51. Fernández-de-las-Peñas, C.; Martín-Guerrero, J.D.; Cancela-Cilleruelo, I.; Moro-López-Menchero, P.; Rodríguez-Jiménez, J.; Pellicer-Valero, O.J. Trajectory curves of post-COVID anxiety/depressive symptoms and sleep quality in previously hospitalized COVID-19 survivors: The LONG-COVID-EXP-CM multicenter study. Psychol. Med. 2022, 1–2. [CrossRef] [PubMed]
52. Iqbal, F.M.; Lam, K.; Sounderajah, V.; Clarke, J.M.; Ashrafian, H.; Darzi, A. Characteristics and predictors of acute and chronic post-COVID symptoms: A systematic review and meta-analysis. EclinicalMedicine 2021, 36, 100899. [CrossRef] [PubMed]
53. Goldstein, C.A.; Kagan, D.; Rizvydeen, M.; Warshaw, M.; Troost, J.P.; Burgess, H.J. The possibility of circadian rhythm disruption in long COVID. Brain Behav. Immun. Health. 2022, 23, 100476. [CrossRef]
54. El Sayed, S.; Gomaa, S.; Shokry, D.; Kabil, A.; Eissa, A. Sleep in post-COVID-19 recovery period and its impact on different domains of quality of life. Egypt J. Neurol. Psychiatr. Neuropsych. 2021, 57, 172. [CrossRef]
55. Nowakowski, S.; Kokonda, M.; Sultana, R.; Duong, B.B.; Nagy, S.E.; Zaidan, M.F.; Baig, M.M.; Grigg, B.V.; Seashore, J.; Deer, R.R. Association between sleep quality and mental health among patients at a post-COVID-19 recovery clinic. Brain Sci. 2022, 12, 586. [CrossRef]
56. Passchier, J.; de Boo, M.; Quaak, H.Z.; Brienhen, J.A. Health-related quality of life of chronic headache patients is predicted by the emotional component of their pain. Headache 1996, 36, 556–560. [CrossRef] [PubMed]
57. Ahmadi Hekmatikar, A.H.; Ferreira Júnior, J.B.; Shahrbanian, S.; Suzuki, K. Functional and psychological changes after exercise training in post-COVID-19 patients discharged from the hospital: A PRISMA-Compliant Systematic Review. *Int. J. Environ. Res. Public Health* **2022**, *19*, 2290. [CrossRef] [PubMed]

58. Cattadori, G.; Di Marco, S.; Baravelli, M.; Picozzi, A.; Ambrosio, G. Exercise training in Post-COVID-19 patients: The need for a multifactorial protocol for a multifactorial pathophysiology. *J. Clin. Med.* **2022**, *11*, 2228. [CrossRef]

59. Whale, K.; Dennis, J.; Wylde, V.; Beswick, A.; Gooberman-Hill, R. The effectiveness of non-pharmacological sleep interventions for people with chronic pain: A systematic review and meta-analysis. *BMC Musculoskelet. Disord.* **2022**, *23*, 44. [CrossRef] [PubMed]

60. Qiu, D.; Li, Y.; Li, L.; He, J.; Ouyang, F.; Xiao, S. Infectious Disease Outbreak and Post-Traumatic Stress Symptoms: A Systematic Review and Meta-Analysis. *Front. Psychol.* **2021**, *12*, 668784. [CrossRef] [PubMed]